| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.30▲ | 1.31▼ | 1.34▼ | 1.31 | 1.43▼ |
| MA10 | 1.31▼ | 1.35▼ | 1.37▼ | 1.31▼ | 1.38▼ |
| MA20 | 1.32▼ | 1.37▼ | 1.33▼ | 1.44▼ | 1.44▼ |
| MA50 | 1.36▼ | 1.31▼ | 1.30▲ | 1.39▼ | 1.72▼ |
| MA100 | 1.37▼ | 1.30▲ | 1.39▼ | 1.44▼ | 3.85▼ |
| MA200 | 1.32▼ | 1.40▼ | 1.44▼ | 1.65▼ | 7.22▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | -0.014▼ | -0.004▼ | -0.017▼ | 0.032▲ |
| RSI | 26.669▼ | 39.916▼ | 45.371▼ | 43.714▼ | 42.878▼ |
| STOCH | 8.889▼ | 7.359▼ | 40.193 | 24.341 | 52.932 |
| WILL %R | -83.333▼ | -96.429▼ | -79.412▼ | -78.750▼ | -70.085 |
| CCI | -76.471 | -126.785▼ | -70.769 | -17.865 | -36.373 |
|
Tuesday, June 23, 2026 10:01 AM
Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small cell lung cancer.
|
|
Tuesday, June 23, 2026 07:28 AM
Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to ...
|
|
Tuesday, June 23, 2026 04:00 AM
Pfizer (PFE) stock is in focus as the antibody-drug conjugate sigvotatug vedotin fails in a Phase 3 trial versus chemotherapy docetaxel in lung cancer. Read more here.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/06/26 | 1.43 | 1.44 | 1.30 | 1.305 | 301,769 |
| 24/06/26 | 1.26 | 1.42 | 1.26 | 1.39 | 571,717 |
| 23/06/26 | 1.25 | 1.30 | 1.25 | 1.28 | 399,340 |
| 22/06/26 | 1.29 | 1.29 | 1.23 | 1.27 | 446,898 |
| 18/06/26 | 1.27 | 1.32 | 1.24 | 1.28 | 619,161 |
| 17/06/26 | 1.23 | 1.29 | 1.23 | 1.25 | 290,070 |
| 16/06/26 | 1.30 | 1.33 | 1.24 | 1.25 | 610,628 |
| 15/06/26 | 1.39 | 1.39 | 1.22 | 1.28 | 751,284 |
| 12/06/26 | 1.5082 | 1.5082 | 1.37 | 1.37 | 226,120 |
| 11/06/26 | 1.42 | 1.44 | 1.35 | 1.42 | 302,610 |
|
|
||||
|
|
||||
|
|